title: Association between two interleukin-2 gene polymorphisms and cancer susceptibility: a meta-analysis.
abstract: BACKGROUND
  Several epidemiological studies have illustrated that polymorphisms in interleukin-2 (IL-2) were associated with diverse cancer types. However, recently published statistics were inconsistent and inconclusive. Therefore, the current meta-analysis was performed to elaborate the effects of IL-2 polymorphisms (rs2069762 and rs2069763) on cancer susceptibility.
  
  
  METHODS
  A total of 5,601 cancer cases and 7,809 controls from 21 published case-control studies were enrolled in our meta-analysis. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association between IL-2 polymorphisms and cancer susceptibility.
  
  
  RESULTS
  Our study demonstrated an increased susceptibility to cancer in rs2069762 (G vs T: OR =1.268, 95% CI =1.113-1.445; GG vs TT: OR =1.801, 95% CI =1.289-2.516; GT vs TT: OR =1.250, 95% CI =1.061-1.473; GG + GT vs TT: OR =1.329, 95% CI =1.118-1.579; GG vs GT + TT: OR =1.536, 95% CI =1.162-2.030). In the subgroup analysis, increased susceptibility to cancer was identified in the hospital-based group and P HWE<0.05 (P-value of the Hardy-Weinberg equilibrium [HWE]) group. In addition, a positive association with cancer susceptibility was observed among both Chinese and non-Chinese. However, no relationship was detected between the rs2069763 polymorphism of IL-2 and cancer susceptibility.
  
  
  CONCLUSIONS
  To conclude, rs2069762 polymorphism of IL-2 contributed to an increased susceptibility to cancer, whereas no association was identified between rs2069763 polymorphism and cancer susceptibility. Further detailed studies are warranted to confirm our findings.
authors.affiliation: Department of Urology, Shenzhen Second People's Hospital, Clinical Medicine of Anhui Medical University, Hefei, Peoples Republic of China; Department of Urology, the First Affiliated Hospital of Anhui Medical University, Hefei, Peoples Republic of China.
authors.forename: Meng
authors.initials: M
authors.lastname: Zhang
authors.affiliation: Department of Urology, Shenzhen Second People's Hospital, Clinical Medicine of Anhui Medical University, Hefei, Peoples Republic of China.
authors.forename: Xiuxiu
authors.initials: X
authors.lastname: Tan
authors.affiliation: Department of Hematology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Peoples Republic of China.
authors.forename: Junjie
authors.initials: J
authors.lastname: Huang
authors.affiliation: Department of Urology, Shenzhen Second People's Hospital, Clinical Medicine of Anhui Medical University, Hefei, Peoples Republic of China.
authors.forename: Lijuan
authors.initials: L
authors.lastname: Xie
authors.affiliation: Department of Urology, Shenzhen Second People's Hospital, Clinical Medicine of Anhui Medical University, Hefei, Peoples Republic of China.
authors.forename: Hao
authors.initials: H
authors.lastname: Wang
authors.affiliation: Department of Urology, Shengli Oilfield Central Hospital, Dongying, Peoples Republic of China.
authors.forename: Jizhou
authors.initials: J
authors.lastname: Shi
authors.affiliation: Department of Urology, Shenzhen Second People's Hospital, Clinical Medicine of Anhui Medical University, Hefei, Peoples Republic of China.
authors.forename: Wei
authors.initials: W
authors.lastname: Lu
authors.affiliation: Department of Urology, Shenzhen Second People's Hospital, Clinical Medicine of Anhui Medical University, Hefei, Peoples Republic of China.
authors.forename: Zhaojie
authors.initials: Z
authors.lastname: Lv
authors.affiliation: Department of Urology, Shenzhen Second People's Hospital, Clinical Medicine of Anhui Medical University, Hefei, Peoples Republic of China.
authors.forename: Hongbing
authors.initials: H
authors.lastname: Mei
authors.affiliation: Department of Urology, the First Affiliated Hospital of Anhui Medical University, Hefei, Peoples Republic of China.
authors.forename: Chaozhao
authors.initials: C
authors.lastname: Liang
keywords: IL-2; cancer; meta-analysis; polymorphism